United States - English - NLM (National Library of Medicine)

sagent pharmaceuticals - melphalan hydrochloride (unii: 1vxp4v453t) (melphalan - unii:q41or9510p) - melphalan 50 mg in 10 ml - melphalan hydrochloride for injection is indicated for the palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate. melphalan should not be used in patients whose disease has demonstrated prior resistance to this agent. patients who have demonstrated hypersensitivity to melphalan should not be given the drug.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - melphalan hydrochloride - powder and solvent for solution for injection - 50mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

alliance healthcare (distribution) ltd - melphalan hydrochloride - powder and solvent for solution for injection - 50mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

tillomed laboratories ltd - melphalan hydrochloride - powder and solvent for solution for injection - 50mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sun pharmaceutical industries europe b.v. - melphalan hydrochloride - powder and solvent for solution for injection - 50mg

Israel - English - Ministry of Health

raz pharmaceutics ltd, israel - melphalan as hydrochloride - powder and solvent for solution for injection/infusion - melphalan as hydrochloride 50 mg - melphalan - for the palliative treatment of multiple myeloma and for the palliation of non resectable epithelial cancer of the ovary.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

aspen pharma trading ltd - melphalan hydrochloride - powder and solvent for solution for injection - 50mg

Ireland - English - HPRA (Health Products Regulatory Authority)

medac gesellschaft für klinische spezialpräparate mbh - melphalan - powder and solvent for solution for injection/infusion - 50 milligram(s) - melphalan

United States - English - NLM (National Library of Medicine)

acrotech biopharma llc - melphalan hydrochloride (unii: 1vxp4v453t) (melphalan - unii:q41or9510p) - melphalan 50 mg in 10 ml - evomela is indicated for use as a high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myeloma. history of serious allergic reaction to melphalan. risk summary based on its mechanism of action, evomela can cause fetal harm when administered to a pregnant woman, including teratogenicity and/or embryo-fetal lethality [see clinical pharmacology (12.1)] . melphalan is a genotoxic drug and can cause chromatid or chromosome damage in humans [see nonclinical toxicology (13.1)] . in animal studies, melphalan was embryolethal and teratogenic in rats at doses below the recommended clinical doses [see data] . advise a pregnant woman of the potential risk to a fetus.. the background risk of major birth defects and miscarriage for the indicated populations are unknown. however, the background risk in the u.s. general population of major birth defects is 2-4% and of miscarriage is 15-20% of clinically recognized pregnancies. data   animal data adequate ani

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

tillomed pharma gmbh - melperone hydrochloride 55,973 mg - eq. melphalan 50 mg - powder and solvent for solution for injection/infusion - 50 mg - melperone hydrochloride 55.973 mg - melphalan